Rocakinogene Sifuplasmid
Phase 1Biologic
Rocakinogene Sifuplasmid is one of 49 biologic programs targeting Chronic Hepatitis C Virus Infection. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
70 competitors in Chronic Hepatitis C Virus Infection
#DrugCompanyPhaseTrials
1Nolvadex
AstraZenecaApproved
Lescol
NovartisApproved
Plaquenil
Alnylam PharmaceuticalsApproved
Actigall
AbbVieApproved
Neoral
NovartisApproved
Avapro
SanofiApproved
Incivek
Vertex PharmaceuticalsPhase 3
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Alinia
RRomark Laboratories L.C.
Approved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rocakinogene Sifuplasmid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)